Targeting Bromodomain-Selective Inhibitors of BET Proteins in Drug Discovery and Development
The DOI matches its Crossref record; 117 of the 117 references it cites were found in a registry or an index.
Abstract
Blocking the interactions between bromodomain and extraterminal (BET) proteins and acetylated lysines of histones by small molecules has important implications for the treatment of cancers and other diseases. Many pan-BET inhibitors have shown satisfactory results in clinical trials, but their potential for poor tolerability and toxicity persist. However, recently reported studies illustrate that some BET bromodomain (BET-BD1 or BET-BD2)-selective inhibitors have advantage over pan-inhibitors, including reduced toxicity concerns. Furthermore, some selective BET inhibitors have similar or even better therapeutic efficacy in inflammatory diseases or cancers. Therefore, the development of selective BET inhibitors has become a hot spot for medicinal chemists. Here, we summarize the known selective BET-BD1 and BET-BD2 inhibitors and review the methods for enhancing the selectivity and potency of these inhibitors based on their different modes of interactions with BET-BD1 or BET-BD2. Finally, we discuss prospective strategies that selectively target the bromodomains of BET proteins.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“These inhibitors are capable of specifically targeting categories, subtypes, and structural domains,491 potentially providing more pronounced benefits in terms of efficacy, safety, and tolerability.67”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [67]
Citations
Cites
Histone Recognition and Large-Scale Structural Analysis of the Human Bromodomain Family
Filippakopoulos, P., Picaud, S., Mangos, M., Keates, T., Lambert, J.-P., Barsyte-Lovejoy, D., Felletar, I., Volkmer, R., Müller, S., Pawson, T., et al. (2012) · Cell · doi:10.1016/j.cell.2012.02.013 · Cited by 1,694
BRD4 and Cancer: going beyond transcriptional regulation
Donati, B., Lorenzini, E., & Ciarrocchi, A. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0915-9 · Cited by 708
The Double Bromodomain-containing Chromatin Adaptor Brd4 and Transcriptional Regulation
Wu, S.-Y., & Chiang, C.-M. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.r700001200 · Cited by 679
Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer
Shu, S., Lin, C. Y., He, H. H., Witwicki, R. M., Tabassum, D. P., Roberts, J. M., Janiszewska, M., Jin Huh, S., Liang, Y., Ryan, J., et al. (2016) · Nature · doi:10.1038/nature16508 · Cited by 632
RVX-208, an inhibitor of BET transcriptional regulators with selectivity for the second bromodomain
Picaud, S., Wells, C., Felletar, I., Brotherton, D., Martin, S., Savitsky, P., Diez-Dacal, B., Philpott, M., Bountra, C., Lingard, H., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1310658110 · Cited by 468
BET Proteins as Targets for Anticancer Treatment
Stathis, A., & Bertoni, F. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0605 · Cited by 463
Selective targeting of BD1 and BD2 of the BET proteins in cancer and immunoinflammation
Gilan, O., Rioja, I., Knezevic, K., Bell, M. J., Yeung, M. M., Harker, N. R., Lam, E. Y. N., Chung, C.-W., Bamborough, P., Petretich, M., et al. (2020) · Science · doi:10.1126/science.aaz8455 · Cited by 422
Amorim, S., Stathis, A., Gleeson, M., Iyengar, S., Magarotto, V., Leleu, X., Morschhauser, F., Karlin, L., Broussais, F., Rezai, K., et al. (2016) · The Lancet Haematology · doi:10.1016/s2352-3026(16)00021-1 · Cited by 417
Small-Molecule Inhibition of BRDT for Male Contraception
Matzuk, M. M., McKeown, M. R., Filippakopoulos, P., Li, Q., Ma, L., Agno, J. E., Lemieux, M. E., Picaud, S., Yu, R. N., Qi, J., et al. (2012) · Cell · doi:10.1016/j.cell.2012.06.045 · Cited by 416
Bromodomains: a new target class for drug development
Cochran, A. G., Conery, A. R., & Sims, R. J. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0030-7 · Cited by 412
Cited by
Zhang, J., Zhang, Y., Wang, J., Xia, Y., Zhang, J., & Chen, L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01911-3 · Cited by 1,138
“588 Iododi fl unisal ( 67 , IDIF), luteolin ( 68 ), and three marketed drugs sulindac ( 69 ), olsalazine ( 70 ), and fl ufenamic ( 71 ) are small-molecule chaperones for the TTR/A β interaction.”
BackgroundSelf-citationEpigenetic drugs in cancer therapy: mechanisms, immune modulation, and therapeutic applications
Ma, C., Cheng, J., Gu, J. H., & Wang, Q. (2025) · Molecular Biomedicine · doi:10.1186/s43556-025-00373-5 · Cited by 66
Targeting bromodomain-containing proteins: research advances of drug discovery
Pan, Z., Zhao, Y., Wang, X., Xie, X., Liu, M., Zhang, K., Wang, L., Bai, D., Foster, L. J., Shu, R., et al. (2023) · Molecular Biomedicine · doi:10.1186/s43556-023-00127-1 · Cited by 44
Jiang, W., Hou, Q., Xu, H., Yang, K., Wang, X., Zhang, K., Zeng, Y., Li, W., Wang, B., Luo, G., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c02104 · Cited by 34
An updated patent review of BRD4 degraders
Ma, Z., Zhang, C., Bolinger, A. A., & Zhou, J. (2024) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2024.2400166 · Cited by 35
Metadata
- Authors
- Chen, J., Tang, P., Wang, Y., Wang, J., Yang, C., Li, Y., Yang, G., Wu, F., Zhang, J., & Ouyang, L.
- Affiliations
- Sichuan University (CN)
- University of Tennessee Health Science Center (US)
- Corresponding author
- Zhang, Jifa
- Ouyang, Liang
- ORCID
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2022-03-24
- Volume
- 65
- Issue
- 7
- Pages
- 5184-5211
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W4220998638
- Cited by
- 62
- References
- 117
- Citations by year
- 2026: 11 · 2025: 16 · 2024: 18 · 2023: 13 · 2022: 4
- FWCI
- 4.16
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- Locations
- Journal of Medicinal Chemistry (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Ministry of Science and Technology of the People's Republic of China (2018ZX09201018-021)
- China Postdoctoral Science Foundation (2020M673268)
- Department of Science and Technology of Sichuan Province (2019YFS0003)
- National Natural Science Foundation of China (81874290, 81903502, 81922064, 82073318)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Histone Deacetylase Inhibitors Research
- Physical Sciences › Chemistry › Organic Chemistry › Heterocyclic Compound Synthesis and Bioactivity
- Keywords
- BET proteins, bromodomain inhibitors, selective inhibitors, histone acetylation, drug selectivity, drug toxicity, cancer therapy, inflammatory diseases, small molecule inhibitors
- MeSH terms
- Protein Domains, Histones, Humans, Neoplasms, Prospective Studies, Transcription Factors, Drug Discovery
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Targeting Bromodomain-Selective Inhibitors of BET Proteins in Drug Discovery and Development. https://app.cochat.ai/papers/10.1021/acs.jmedchem.1c01835
- The paper
- Chen, J., Tang, P., Wang, Y., Wang, J., Yang, C., Li, Y., Yang, G., Wu, F., Zhang, J., & Ouyang, L. (2022). Targeting Bromodomain-Selective Inhibitors of BET Proteins in Drug Discovery and Development. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.1c01835
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.